Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas

Molecular Biology Reports

Volumn 39, Issue 2, 2012, Pages 1595-1599

  Silan, Fatma ^a   Gultekin, Yener ^b   Atik, Sinem ^a   Kilinc, Davran ^b   Alan, Cabir ^a   Yildiz, Fazilet ^b   Uludag, Ahmet ^a   Ozdemir, Ozturk ^a,b  

^a ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

^b CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Codon 12 and 13; Combined point mutation; KRAS proto oncogene; Prostate carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; ONCOGENE K RAS; POINT MUTATION; PREDICTION; PREVALENCE; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; SMALL CELL CARCINOMA; CARCINOMA; DNA SEQUENCE; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROSTATE TUMOR;

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

BASE SEQUENCE; CARCINOMA; GENOTYPE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; POINT MUTATION; PREVALENCE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84860344694     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0898-8     Document Type: Article

References (27)

1. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ et al (2002) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 167(2 Pt 2):966-973
2. Eisenberg ML, Park Y, Brinton LA, Hollenbeck AR, Schatzkin A (2010) Fatherhood and incident prostate cancer in a prospective US cohort. Int J Epidemiol. [Epub ahead of print]
3. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et, al. (2010) EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Eur Urol. [Epub ahead of print]
4. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6, 630 men. J Urol 151(5):1283-1290 (Pubitemid 24121936)
5. Damber JE, Aus G (2008) Prostate cancer. Lancet 371(9625): 1710-1721 (Pubitemid 351671887)
6. Ma CG, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL et al. (2010) The survival analysis of metastatic prostate cancer. Zhonghua Wai Ke Za Zhi. (15):1166-1169
7. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27(7):1130-1136
8. Chen J, Huang XF, Katsifis A (2010) Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J Cell Biochem 111(5):1082-1086
9. Mariani P, Lae M, Degeorges A, Cacheux W, Lappartient E, Margogne A et al (2010) Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res 30(10):4229-4235
10. Shen Y, Lu Y, Yin X, Zhu G, Zhu J (2010) KRAS and BRAF mutations in prostate carcinomas of Chinese patients. Cancer Genet Cytogenet 198(1):35-39
11. Van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT et al (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453(5):417-431
12. de Launay D, Vreijling J, Hartkamp LM, Karpus ON, Abreu JR, van Maanen MA et al (2010) Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis. Am J Pathol 177(6): 3010-3024
13. Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M et al (2011) The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colo-rectal cancer tissues. Jpn J Clin Oncol 41(2):165-171
14. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C et al (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1(2):203-209 (Pubitemid 41039166)
15. Arslan S, Dogan T, Koksal B, Yildirim ME, Gumus C, Elagoz S, Akkurt I, Ozdemir O (2008) Tumoral tissue specific promoter hypermethylation of distinct tumor suppressor genes in a case with non-small cell lung carcinoma: a case report. Lung India 25:148-151
16. Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q et al (2010) TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 23(10):1325-1333
17. Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M et al (2010) Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 102(17):1336-1343
18. Pergolizzi RG, Kreis W, Rottach C, Susin M, Broome JD (1993) Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. Cancer Invest 11(1):25-32 (Pubitemid 23041446)
19. Shibata D, Capella G, Perucho M (1990) Mutational activation of the c-K-ras gene in human pancreatic carcinoma. Baillieres Clin Gastroenterol 4(1):151-169 (Pubitemid 20302039)
20. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K et al (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342(6250):705-708 (Pubitemid 20001591)
21. Tartaglia M, Gelb BD (2010) Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci 1214:99-121
22. Capella G, Cronauer-Mitra S, Peinado MA, Perucho M (1991) Frequency and spectrum of mutations at codons 12 and 13 of the C-K-ras gene in human tumors. Environ Health Perspect 93:125-131
23. Watanabe M, Shiraishi T, Yatani R, Nomura AM, Stemmermann GN (1994) International comparison on ras gene mutations in latent prostate carcinoma. Int J Cancer 58(2):174-178 (Pubitemid 24240091)
24. Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24(18): 1967-2000
25. Gallagher DJ, Feifer A, Coleman JA (2010) Genitourinary cancer predisposition syndromes. Hematol Oncol Clin North Am 24(5):861-883
26. Schulz WA, Hoffmann MJ (2009) Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 12:172-180
27. Konishi N, Hiasa Y, Tsuzuki T, Tao M, Enomoto T, Miller GJ (1997) Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 30(1):53-57 (Pubitemid 27053541)